Skip to main content

Table 1 Number of patients (%) for patient and tumor characteristics of each treatment group

From: Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma

Characteristics

Complete TACE

Incomplete TACE

P-value

Curative Tx

SABR

Non-curative Tx

Age

    

0.622

 Range (median, years)

41–83 (55)

35–77 (60)

42–74 (59)

24–84 (59)

 

Sex

    

0.426

 Male

14 (58)

33 (70)

29 (78)

49 (70)

 

 Female

10 (42)

14 (30)

8 (22)

21 (30)

 

BCLC stage

    

0.135

 0

9 (38)

8 (17)

6 (16)

12 (17)

 

 A

15 (63)

39 (83)

31 (84)

58 (83)

 

CTP score

    

0.040

 5

18 (75)

42 (89)

26 (70)

47 (67)

 

 6

3 (13)

5 (11)

7 (19)

16 (23)

 

 7

3 (13)

0 ( 0)

4 (11)

7 (10)

 

Tumor size

    

0.073

 Range (median, cm)

0.5–8 (2.1)

1–8 (2.8)

0.8–10 (3.4)

0.5–10 (3.8)

 

 0.1–3.0 cm

19 (79)

32 (68)

18 (49)

36 (51)

 

 3.1–10.0 cm

5 (21)

15 (32)

19 (51)

34 (49)

 
  1. Abbreviations: TACE transcatheter arterial chemoembolization, Tx treatment, SABR stereotactic ablative radiotherapy, BCLC Barcelona Clinic Liver Cancer, CTP Child-Turcotte-Pugh